A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether piboserod, a serotonin-4 receptor antagonist, is effective for the treatment of patients with congestive heart failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bio-Medisinsk Innovasjon
• Collaborator: Smerud Medical Research International AS

Criteria

Inclusion Criteria:

• Clinical diagnosis of CHF (NYHA class II-IV)

• Locally determined LVEF < 0.35 (by CMR, echocardiography, LV angiography, or radionuclide cardioangiography)

• Stable sinus rhythm

• Stable evidence based pharmacological treatment for CHF.

Exclusion Criteria:

• Unstable patients hospitalised within last 2 weeks

• Baseline prolongation of QTc interval

• Atrial fibrillation at randomisation

• MI or re-vascularisation last 3 months

• Stroke last 3 months.